Recruiting

Testing a new treatment for moderate-to-severe eczema in adults

Plain-English translation of NCT07599813 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Read our Atopic Dermatitis research guide →

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called to see if it can help adults with moderate-to-severe eczema (atopic dermatitis) get better control of their skin symptoms. The study will compare three different doses of this medication against a placebo (dummy injection) over 24 weeks to find out which dose works best and is safest. After the first phase, everyone in the study will have the option to receive the medication.

Many people with severe eczema don't get enough relief from current treatments like creams and steroids. This trial is testing whether this new medication could offer a better option for people whose eczema is not controlled well enough with existing therapies.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have been diagnosed with moderate-to-severe eczema for at least one year
your eczema covers at least 10% of your body or causes significant itching despite previous treatment attempts
you have tried topical creams or ointments for at least 28 days without adequate improvement, or cannot use them safely
you are willing to use reliable contraception during the study if you can become pregnant

You likely don't qualify if…

you have a serious untreated mental health condition, severe depression, or past suicide attempt within the last 10 years
you have an active infection requiring antibiotics, antivirals, or antifungal medications within the last 2 weeks
you have another active skin disease like psoriasis or a current skin infection that could affect the study results
you have had a severe eczema flare-up in the 4 weeks before screening
you have uncontrolled asthma or severe allergies that are not well-managed with current treatments

What participation looks like

If you join this study, you will receive either the new medication or a placebo injection under the skin, along with three different dose strengths being tested. The first part lasts 24 weeks, during which you'll have regular visits to measure how your skin is improving and check for any side effects. After that, all participants move into a second phase where everyone receives the active medication so researchers can continue monitoring safety and benefits.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(85 sites)

United States

AllerVie Clinical Research, Birmingham, Alabama

Cahaba Dermatology and Skin Health Center, Birmingham, Alabama

Saguaro Dermatology Associates, Phoenix, Arizona

Dermatology Trial Associates, Inc, Bryant, Arkansas

Marvel Research, LLC, Huntington Beach, California